Sun.Nov 20, 2022

article thumbnail

Why 1 VC is Fed Up with the Concept of Digital Health Unicorns

MedCity News

There are currently 97 global digital health companies that are considered unicorns. But getting caught up with the idea of digital health unicorns isn’t very sustainable, according to Emilly Melton, managing partner at Threshold Ventures. Instead of focusing too much on their valuations, she recommended that startups simply focus on getting the capital they need in order to reach the next stage of inflection.

article thumbnail

NICE questions value and efficacy of five Covid-19 drugs with rejection

Pharmaceutical Technology

The UK's National Institute for Health and Care Excellence (NICE) has published a draft guidance that does not recommend the use of five major Covid-19 therapies. This news came as many organisations and patient advocacy groups have been campaigning for the adoption of some of the rejected drugs for several months, amidst concerns about access to medicines in the UK.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

When It Comes to Dental Care, Convenience Isn’t a Luxury

MedCity News

For far too long, dentists have focused on drilling and billing rather than optimizing the patient experience — and that’s driving many of our patients away, with terrible results for their dental health.

Patients 117
article thumbnail

Ex-Theranos CEO Elizabeth Holmes sentenced to 11 years

pharmaphorum

Elizabeth Holmes, the founder and former chief executive of blood testing biotech Theranos, has been sentenced after being convicted of defrauding investors in the company earlier this year, receiving a prison sentence of more than 11 years in a California court. That’s shorter than the 15 years sought by prosecutors, but considerably longer than the 18 months’ house arrest that Holmes’ defense attorneys had pushed for, and there is likely to be an appeal against the sentence,

FDA 120
article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

article thumbnail

Acrivon Nets $100M for Protein Tech That Picks Patients for Targeted Cancer Meds

MedCity News

Eli Lilly’s stalled cancer drug prexasertib has another chance under Acrivon Therapeutics, whose IPO will fund a fresh slate of mid-stage clinical trials. While attention is focused on the former Lilly asset, also at stake is Acrivon’s technology platform that relies on proteomics rather than genomics for identifying patients appropriate for targeted therapies.

Patients 107
article thumbnail

Overcoming the challenges of developing vaccines in an accelerated timeframe

pharmaphorum

The COVID-19 pandemic stopped the world in its tracks. It provided a range of new challenges for industry stakeholders, including governments, public health bodies, and regulatory agencies – to name a few. In addition, it offered the opportunity for new solutions and approaches to many of today’s healthcare challenges. The world responded to the crisis at unprecedented speed, as leaders and experts focused on different ways to operate and succeed within the constraints of a new dynamic.

More Trending

article thumbnail

Health Canada grants expanded authorisation for Novavax’s Covid-19 vaccine

Pharmaceutical Technology

Health Canada has granted expanded authorisation for Novavax ’s Covid-19 vaccine (Recombinant protein, Adjuvanted) [Nuvaxovid; NVX-CoV2373] as a homologous booster for usage in adults aged 18 and above. The vaccine is indicated for active immunisation to prevent the disease. The latest development was based on findings from a Phase II clinical trial of the vaccine in South Africa as well as from the Phase III Prevent-19 trial in the US and Mexico.

article thumbnail

Are We in a Recession? Executives at HLTH Weigh In

MedCity News

MedCity News interviews CEOs of public companies, entrepreneurs, VCs and payers who had a range of varying answers to the question. But one common theme emerged: everyone, currently, has a vise-like grip on expenditure.

article thumbnail

GSK’s pullback from cell therapy continues as Immatics alliance ends

pharmaphorum

Immatics has become the latest partner for GSK in the area of cell therapy for cancer to see its alliance shelved, just two and a half years after being set up. In its third-quarter results update , the Tuebingen, Germany-based biotech said it had been informed by GSK in early October that it would be terminating their partnership announced in February 2020, adding that the decision was made “unrelated to the programmes and the progress achieved in the collaboration to date.” The de

Leads 57
article thumbnail

Pharmacovigilance in the 21st Century: How to Improve Real-World Safety Reporting through Point-of-Care Technology

PharmExec

Webinar Date/Time: Thu, Dec 8, 2022 2:00 PM EST.

Safety 52
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.